CYTK
Price
$32.08
Change
-$0.33 (-1.02%)
Updated
Jun 5 closing price
Capitalization
3.83B
55 days until earnings call
KRYS
Price
$132.62
Change
+$0.59 (+0.45%)
Updated
Jun 5 closing price
Capitalization
3.84B
66 days until earnings call
Interact to see
Advertisement

CYTK vs KRYS

Header iconCYTK vs KRYS Comparison
Open Charts CYTK vs KRYSBanner chart's image
Cytokinetics
Price$32.08
Change-$0.33 (-1.02%)
Volume$1.02M
Capitalization3.83B
Krystal Biotech
Price$132.62
Change+$0.59 (+0.45%)
Volume$233.16K
Capitalization3.84B
CYTK vs KRYS Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. KRYS commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and KRYS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (CYTK: $32.08 vs. KRYS: $132.73)
Brand notoriety: CYTK and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 46% vs. KRYS: 65%
Market capitalization -- CYTK: $3.83B vs. KRYS: $3.84B
CYTK [@Biotechnology] is valued at $3.83B. KRYS’s [@Biotechnology] market capitalization is $3.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileKRYS’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • KRYS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while KRYS’s TA Score has 6 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 3 bearish.
  • KRYS’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а +2.43% price change this week, while KRYS (@Biotechnology) price change was +5.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.84B) and CYTK($3.83B) have the same market capitalization . KRYS YTD gains are higher at: -15.275 vs. CYTK (-31.803). KRYS has higher annual earnings (EBITDA): 140M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. KRYS (617M). KRYS has less debt than CYTK: KRYS (9.66M) vs CYTK (791M). KRYS has higher revenues than CYTK: KRYS (333M) vs CYTK (19.2M).
CYTKKRYSCYTK / KRYS
Capitalization3.83B3.84B100%
EBITDA-513.62M140M-367%
Gain YTD-31.803-15.275208%
P/E RatioN/A31.83-
Revenue19.2M333M6%
Total Cash938M617M152%
Total Debt791M9.66M8,187%
FUNDAMENTALS RATINGS
CYTK vs KRYS: Fundamental Ratings
CYTK
KRYS
OUTLOOK RATING
1..100
35
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
8448
SMR RATING
1..100
9957
PRICE GROWTH RATING
1..100
8888
P/E GROWTH RATING
1..100
197
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (69) in the Pharmaceuticals Major industry is in the same range as CYTK (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CYTK’s over the last 12 months.

KRYS's Profit vs Risk Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for CYTK (84) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than CYTK’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for CYTK (99) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than CYTK’s over the last 12 months.

KRYS's Price Growth Rating (88) in the Pharmaceuticals Major industry is in the same range as CYTK (88) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for KRYS (97) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKKRYS
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
78%
Bearish Trend 15 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SUWCX30.68N/A
N/A
DWS Core Equity C
CFIZX13.98N/A
N/A
Columbia Flexible Capital Income Inst
MSAQX22.48N/A
N/A
Morgan Stanley Inst Asia Opp I
VTISX153.22N/A
N/A
Vanguard Total Intl Stock Idx Instl Sel
GSRFX12.24N/A
N/A
Goldman Sachs Rising Dividend Gr R6

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with KRYS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-1.02%
KRYS - CYTK
47%
Loosely correlated
+0.53%
IDYA - CYTK
47%
Loosely correlated
-0.09%
TRDA - CYTK
44%
Loosely correlated
+2.14%
ACLX - CYTK
44%
Loosely correlated
+1.18%
ROIV - CYTK
44%
Loosely correlated
-0.18%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+0.53%
ACLX - KRYS
57%
Loosely correlated
+1.18%
IDYA - KRYS
56%
Loosely correlated
-0.09%
CGON - KRYS
54%
Loosely correlated
+0.23%
CRNX - KRYS
54%
Loosely correlated
+0.59%
XNCR - KRYS
53%
Loosely correlated
+0.22%
More